RxDoctor Payments Data

Maryna Popp, DO

Interventional Cardiology · Springfield, ILNPI 1326486515

Payments from drug & device makers

$5,751in general payments, 2019–2025

Across 204 payments — averaging $28.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$3K
  • Novartis$792
  • Amgen$501
  • AstraZeneca$273
  • Medtronic$267
  • Abbott$261
  • plus $917 from 12 others

What the payments were for

  • Speaking & faculty fees$5009%
  • Travel & lodging$2,18538%
  • Food & beverage$2,98452%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,751 in reported general payments places this provider in the 35th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$371,528
Medicare patients
2,006
Services billed
7,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban486$624,488
EntrestoSacubitril/Valsartan159$212,965
JardianceEmpagliflozin153$175,050
Repatha SureclickEvolocumab137$139,384
XareltoRivaroxaban101$104,921
BrilintaTicagrelor74$81,226
Repatha PushtronexEvolocumab93$72,749
Praluent PenAlirocumab61$47,136
Metoprolol Succinate675$7,677
Ranolazine ErRanolazine72$7,603
NexletolBempedoic Acid13$6,863
Potassium Chloride150$3,902
Isosorbide Mononitrate ErIsosorbide Mononitrate311$3,123
Atorvastatin Calcium415$3,104
Torsemide117$2,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$624,488486 claims
NovartisEntresto$792$212,965159 claims
Boehringer IngelheimJardiance$31$175,050153 claims
Johnson & JohnsonXarelto$58$104,921101 claims
AstraZenecaBrilinta$273$81,22674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →